Tuberculosis Treatment Insurance Claim Denied? How to Appeal

Tuberculosis is one of the most serious infectious diseases in the world, and in the United States it remains a significant public health concern. Both active TB disease and latent TB infection (LTBI) require treatment — active TB with a multi-drug regimen typically lasting six months or longer, and latent TB with shorter prophylactic regimens to prevent progression to active disease. Denials of TB treatment coverage are not just harmful to individual patients; they have serious public health implications. Fortunately, a combination of legal appeal rights and public health safety-net programs can help ensure you receive the care you need.

Why Insurers Deny Tuberculosis Treatment

Latent TB treatment classified as "not medically necessary." Insurers sometimes deny treatment for latent TB infection — where the patient has a positive tuberculin skin test (TST) or IGRA blood test but no symptoms of active disease — characterizing preventive therapy as elective or unnecessary. This is clinically incorrect: LTBI treatment is a standard preventive intervention that reduces the lifetime risk of progression to active TB by up to 90 percent. CDC and USPSTF guidelines explicitly recommend treatment for LTBI, and the ICD-10 code for latent TB infection is Z22.7.

Drug formulary restrictions on preferred TB regimens. Standard first-line TB treatment for active disease (ICD-10: A15.x for pulmonary TB, A17.x–A19.x for extrapulmonary and miliary TB) includes isoniazid (INH), rifampin, pyrazinamide, and ethambutol — the RIPE regimen. Shorter LTBI treatment regimens such as 3HP (once-weekly rifapentine plus isoniazid for 12 weeks) or 4R (four months of daily rifampin) are recommended by CDC and the ATS/CDC/ERS/IDSA guidelines. Formulary restrictions on rifapentine or rifampin may block access to these preferred regimens.

Directly Observed Therapy (DOT) services denied. Directly Observed Therapy — where a health worker observes the patient taking each dose of TB medication — is the standard of care recommended by CDC for ensuring treatment completion and preventing drug resistance. Insurers may deny coverage for DOT services, arguing they are not covered medical services. In practice, DOT is often provided free of charge by local or state health departments, but when private coverage for DOT is needed, denials should be appealed.

Drug-resistant TB treatment denied as experimental. Multidrug-resistant TB (MDR-TB, ICD-10: A15.0 with drug-resistance qualifier) and extensively drug-resistant TB (XDR-TB) require prolonged regimens using second-line agents including bedaquiline, delamanid, linezolid, and clofazimine. Insurers may classify these newer agents as experimental despite FDA approval and WHO/CDC guidance supporting their use. Bedaquiline received FDA approval for MDR-TB in 2012.

Coverage gaps in immigrant and high-risk populations. TB disproportionately affects foreign-born individuals, people experiencing homelessness, correctional populations, and immunocompromised patients (including those with HIV/AIDS, ICD-10: B20, or on immunosuppressive therapy). Medicaid and other safety-net coverage gaps in these populations create situations where TB treatment is not covered — but public health funding and CDC-supported TB programs provide an important backstop.

How to Appeal a Tuberculosis Treatment Denial

Step 1: Engage Your Local or State TB Control Program Immediately

Before or while pursuing the insurance appeal, contact your local or state health department's TB control program. In the United States, state TB control programs receive CDC funding and are legally required to ensure treatment for all TB cases regardless of insurance status. The public health system can provide medications, DOT services, and case management as a safety net. This does not end your right to appeal the insurance denial — but it ensures you receive treatment while the appeal proceeds.

Step 2: Obtain CDC and ATS/CDC/ERS/IDSA Guideline Documentation

The definitive clinical authority for TB treatment is the 2016 ATS/CDC/ERS/IDSA guidelines for treatment of drug-susceptible TB, and the 2019 WHO consolidated guidelines for drug-resistant TB. For LTBI, the 2020 ATS/IDSA/CDC Clinical Practice Guidelines recommend 3HP, 4R, or 6H (six months of daily isoniazid) regimens. Download and attach the relevant guideline pages to your appeal, citing the specific recommendation for the denied treatment. The ICD-10 code for the condition treated should be included: A15.x for pulmonary TB, Z22.7 for LTBI.

Step 3: Obtain a Comprehensive Physician Letter

Your treating infectious disease specialist or TB clinician should document: the specific diagnosis with ICD-10 code; susceptibility testing results (or prior treatment history for MDR-TB cases); the specific treatment regimen denied and the clinical rationale for selecting it; the ATS/CDC/ERS/IDSA guideline recommendation for this regimen; why alternative regimens are not appropriate (drug resistance, patient tolerance, drug interactions, or HIV coinfection requiring specific drug combinations); and the public health importance of completing the full treatment course.

Step 4: Challenge Experimental Classification for Newer Agents

If the denial classifies bedaquiline, delamanid, or other newer MDR-TB agents as experimental, provide: FDA approval documentation; WHO and CDC guidance supporting their use; the patient's susceptibility testing results demonstrating the need for these agents; and evidence from published clinical trials demonstrating efficacy. The FDA approved bedaquiline for MDR-TB under accelerated approval in 2012, and extensive real-world evidence since then supports its use.

Step 5: File the Internal Appeal

Submit within 180 days of denial under ACA Section 2719 (42 U.S.C. § 300gg-19) for commercial plans, or through the appropriate Medicaid appeal process for Medicaid enrollees. Include the physician's letter, susceptibility testing results, guideline excerpts, FDA approval documentation for any denied drugs, and a direct rebuttal of each denial reason. Request review by a board-certified infectious disease specialist.

Step 6: File a State Insurance Commissioner Complaint

File a complaint with your state insurance commissioner documenting the denial and its public health implications. Many states have laws requiring coverage of CDC-recommended preventive services, which may include LTBI treatment. The public health urgency of TB treatment creates additional regulatory pressure for prompt resolution.

What to Include in Your Appeal

• Denial letter with specific stated reason and the policy provision or formulary restriction applied
• Physician's letter with ICD-10 diagnosis code (A15.x for active pulmonary TB, A17.x–A19.x for extrapulmonary TB, Z22.7 for LTBI), susceptibility testing results, and ATS/CDC/ERS/IDSA guideline citation
• ATS/CDC/ERS/IDSA guideline excerpt for the specific TB treatment regimen denied
• FDA approval documentation for any denied newer TB agents (bedaquiline, delamanid)
• Susceptibility testing results demonstrating the clinical need for the specific drug regimen requested
• Documentation of public health program coordination (state/local TB program contact) showing the treatment is CDC-recommended standard of care

Fight Back With ClaimBack

Tuberculosis treatment denials are both medically urgent and publicly significant — untreated TB affects not only the patient but the broader community. ATS/CDC guideline citations, susceptibility testing results, and FDA approval documentation make these appeals highly persuasive when assembled correctly. Public health safety-net programs can bridge coverage gaps while you appeal, but you still have the right to insurance coverage for your treatment. ClaimBack generates a professional appeal letter in 3 minutes, citing the clinical guidelines, ICD-10 codes, and legal protections that apply to your TB treatment denial.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal